Abstract
An attempt was made to determine the plasma ergotamine concentrations in nine male patients with cluster headache 15–600 min after oral therapeutic doses of ergotamine tartrate (Cafergot(r)). Some of the patients were studied twice. Five patients received a constant dose of 2–4 mg daily for at least seven days. Four patients were given 1 mg five times on one day and three patients a single oral dose of 2 mg. Ergotamine was determined by means of high performance liquid chromatography with fluorescence detection-a new highly sensitive, specific method, the detection limit of which is less than 100 pg/ml for ergotamine. Ergotamine tartrate was not discovered in any of the plasma samples. In one patient ergotamine could not be detected in the cerebrospinal fluid one hour after a single oral dose of 2 mg. The oral biological availability is less than 1%, which is the maximal available fraction of unchanged ergotamine after oral administration. A clinical benefit was observed in several of our patients. These effects of the drug may be because of active metabolites being formed and/or to high affinity of ergotamine to cranial vessels.
Get full access to this article
View all access options for this article.